BioN­Tech read­ies for plunge in Covid sales, will boost mR­NA and on­col­o­gy pipelines

BioN­Tech is es­ti­mat­ing €5 bil­lion (near­ly $5.4 bil­lion) in Covid-19 vac­cine sales this year, a marked drop from €17.1 bil­lion ($18.5 bil­lion) in 2022 — and way off an­a­lysts’ ex­pec­ta­tions of around €8 bil­lion ($8.6 bil­lion).

In BioN­Tech’s year-end earn­ings call on Mon­day, it re­port­ed a to­tal of €17.3 bil­lion ($18.7 bil­lion) in 2022 rev­enue, al­most all from vac­cine sales, which in­clude those via its Pfiz­er deal and di­rect sales.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER